nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Tamoxifen—pancreatic cancer	0.0375	0.199	CbGbCtD
Carfilzomib—ABCB1—Gemcitabine—pancreatic cancer	0.0323	0.172	CbGbCtD
Carfilzomib—ABCB1—Erlotinib—pancreatic cancer	0.0319	0.169	CbGbCtD
Carfilzomib—ABCB1—Irinotecan—pancreatic cancer	0.0288	0.153	CbGbCtD
Carfilzomib—ABCB1—Docetaxel—pancreatic cancer	0.0211	0.112	CbGbCtD
Carfilzomib—ABCB1—Sunitinib—pancreatic cancer	0.021	0.112	CbGbCtD
Carfilzomib—Pentagastrin—CCKBR—pancreatic cancer	0.0184	1	CrCbGaD
Carfilzomib—ABCB1—Doxorubicin—pancreatic cancer	0.0157	0.0835	CbGbCtD
Carfilzomib—PSMB8—islet of Langerhans—pancreatic cancer	0.0095	0.126	CbGeAlD
Carfilzomib—PSMB10—digestive system—pancreatic cancer	0.00885	0.118	CbGeAlD
Carfilzomib—PSMB5—islet of Langerhans—pancreatic cancer	0.00839	0.112	CbGeAlD
Carfilzomib—PSMB1—islet of Langerhans—pancreatic cancer	0.00734	0.0975	CbGeAlD
Carfilzomib—PSMB2—islet of Langerhans—pancreatic cancer	0.00716	0.0952	CbGeAlD
Carfilzomib—PSMB8—pancreas—pancreatic cancer	0.00668	0.0888	CbGeAlD
Carfilzomib—PSMB2—Azacitidine—Gemcitabine—pancreatic cancer	0.00635	1	CbGdCrCtD
Carfilzomib—PSMB5—pancreas—pancreatic cancer	0.0059	0.0784	CbGeAlD
Carfilzomib—PSMB1—pancreas—pancreatic cancer	0.00516	0.0686	CbGeAlD
Carfilzomib—PSMB2—pancreas—pancreatic cancer	0.00503	0.0669	CbGeAlD
Carfilzomib—PSMB1—digestive system—pancreatic cancer	0.0044	0.0586	CbGeAlD
Carfilzomib—PSMB2—digestive system—pancreatic cancer	0.0043	0.0571	CbGeAlD
Carfilzomib—ABCB1—islet of Langerhans—pancreatic cancer	0.00109	0.0145	CbGeAlD
Carfilzomib—Arthralgia—Tamoxifen—pancreatic cancer	0.000805	0.00227	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Fluorouracil—pancreatic cancer	0.000801	0.00226	CcSEcCtD
Carfilzomib—Arthralgia—Erlotinib—pancreatic cancer	0.000796	0.00225	CcSEcCtD
Carfilzomib—Back pain—Sunitinib—pancreatic cancer	0.000783	0.00221	CcSEcCtD
Carfilzomib—Muscle spasms—Sunitinib—pancreatic cancer	0.000778	0.0022	CcSEcCtD
Carfilzomib—ABCB1—pancreas—pancreatic cancer	0.000769	0.0102	CbGeAlD
Carfilzomib—Hyponatraemia—Docetaxel—pancreatic cancer	0.000769	0.00217	CcSEcCtD
Carfilzomib—Infection—Tamoxifen—pancreatic cancer	0.000766	0.00216	CcSEcCtD
Carfilzomib—Pain in extremity—Docetaxel—pancreatic cancer	0.000766	0.00216	CcSEcCtD
Carfilzomib—Infection—Erlotinib—pancreatic cancer	0.000758	0.00214	CcSEcCtD
Carfilzomib—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.000755	0.00213	CcSEcCtD
Carfilzomib—Anaemia—Sunitinib—pancreatic cancer	0.000748	0.00211	CcSEcCtD
Carfilzomib—Thrombocytopenia—Erlotinib—pancreatic cancer	0.000747	0.00211	CcSEcCtD
Carfilzomib—Anorexia—Tamoxifen—pancreatic cancer	0.000735	0.00207	CcSEcCtD
Carfilzomib—Oedema peripheral—Gemcitabine—pancreatic cancer	0.000735	0.00207	CcSEcCtD
Carfilzomib—Hypoaesthesia—Fluorouracil—pancreatic cancer	0.00073	0.00206	CcSEcCtD
Carfilzomib—Anorexia—Erlotinib—pancreatic cancer	0.000728	0.00205	CcSEcCtD
Carfilzomib—Leukopenia—Sunitinib—pancreatic cancer	0.000725	0.00204	CcSEcCtD
Carfilzomib—Cardiac disorder—Irinotecan—pancreatic cancer	0.000711	0.00201	CcSEcCtD
Carfilzomib—Cough—Sunitinib—pancreatic cancer	0.000706	0.00199	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.000703	0.00198	CcSEcCtD
Carfilzomib—Hypertension—Sunitinib—pancreatic cancer	0.000699	0.00197	CcSEcCtD
Carfilzomib—Insomnia—Tamoxifen—pancreatic cancer	0.000698	0.00197	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000695	0.00196	CcSEcCtD
Carfilzomib—Cardiac disorder—Gemcitabine—pancreatic cancer	0.000693	0.00195	CcSEcCtD
Carfilzomib—Insomnia—Erlotinib—pancreatic cancer	0.00069	0.00195	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Docetaxel—pancreatic cancer	0.000689	0.00194	CcSEcCtD
Carfilzomib—Arthralgia—Sunitinib—pancreatic cancer	0.000689	0.00194	CcSEcCtD
Carfilzomib—Dyspnoea—Tamoxifen—pancreatic cancer	0.000688	0.00194	CcSEcCtD
Carfilzomib—Chills—Irinotecan—pancreatic cancer	0.000687	0.00194	CcSEcCtD
Carfilzomib—Dyspnoea—Erlotinib—pancreatic cancer	0.000681	0.00192	CcSEcCtD
Carfilzomib—Decreased appetite—Tamoxifen—pancreatic cancer	0.000671	0.00189	CcSEcCtD
Carfilzomib—Chills—Gemcitabine—pancreatic cancer	0.00067	0.00189	CcSEcCtD
Carfilzomib—Fatigue—Tamoxifen—pancreatic cancer	0.000665	0.00188	CcSEcCtD
Carfilzomib—Decreased appetite—Erlotinib—pancreatic cancer	0.000664	0.00187	CcSEcCtD
Carfilzomib—Pain—Tamoxifen—pancreatic cancer	0.00066	0.00186	CcSEcCtD
Carfilzomib—Constipation—Tamoxifen—pancreatic cancer	0.00066	0.00186	CcSEcCtD
Carfilzomib—Fatigue—Erlotinib—pancreatic cancer	0.000658	0.00186	CcSEcCtD
Carfilzomib—ABCB1—digestive system—pancreatic cancer	0.000656	0.00873	CbGeAlD
Carfilzomib—Infection—Sunitinib—pancreatic cancer	0.000656	0.00185	CcSEcCtD
Carfilzomib—Pain—Erlotinib—pancreatic cancer	0.000653	0.00184	CcSEcCtD
Carfilzomib—Constipation—Erlotinib—pancreatic cancer	0.000653	0.00184	CcSEcCtD
Carfilzomib—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000647	0.00182	CcSEcCtD
Carfilzomib—Back pain—Irinotecan—pancreatic cancer	0.000645	0.00182	CcSEcCtD
Carfilzomib—Muscle spasms—Irinotecan—pancreatic cancer	0.000641	0.00181	CcSEcCtD
Carfilzomib—Anorexia—Sunitinib—pancreatic cancer	0.00063	0.00178	CcSEcCtD
Carfilzomib—Back pain—Gemcitabine—pancreatic cancer	0.000628	0.00177	CcSEcCtD
Carfilzomib—Neutropenia—Docetaxel—pancreatic cancer	0.000619	0.00174	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—pancreatic cancer	0.000617	0.00174	CcSEcCtD
Carfilzomib—Anaemia—Irinotecan—pancreatic cancer	0.000616	0.00174	CcSEcCtD
Carfilzomib—Body temperature increased—Erlotinib—pancreatic cancer	0.000603	0.0017	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000602	0.0017	CcSEcCtD
Carfilzomib—Anaemia—Gemcitabine—pancreatic cancer	0.0006	0.00169	CcSEcCtD
Carfilzomib—Insomnia—Sunitinib—pancreatic cancer	0.000598	0.00169	CcSEcCtD
Carfilzomib—Leukopenia—Irinotecan—pancreatic cancer	0.000597	0.00168	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—pancreatic cancer	0.000593	0.00167	CcSEcCtD
Carfilzomib—Anaemia—Fluorouracil—pancreatic cancer	0.00059	0.00166	CcSEcCtD
Carfilzomib—Dyspnoea—Sunitinib—pancreatic cancer	0.000589	0.00166	CcSEcCtD
Carfilzomib—Cough—Irinotecan—pancreatic cancer	0.000582	0.00164	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.000582	0.00164	CcSEcCtD
Carfilzomib—Leukopenia—Gemcitabine—pancreatic cancer	0.000582	0.00164	CcSEcCtD
Carfilzomib—Renal failure—Docetaxel—pancreatic cancer	0.00058	0.00164	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—pancreatic cancer	0.000578	0.00163	CcSEcCtD
Carfilzomib—Hypertension—Irinotecan—pancreatic cancer	0.000576	0.00162	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—pancreatic cancer	0.000575	0.00162	CcSEcCtD
Carfilzomib—Decreased appetite—Sunitinib—pancreatic cancer	0.000574	0.00162	CcSEcCtD
Carfilzomib—Leukopenia—Fluorouracil—pancreatic cancer	0.000572	0.00161	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—pancreatic cancer	0.000571	0.00161	CcSEcCtD
Carfilzomib—Fatigue—Sunitinib—pancreatic cancer	0.00057	0.00161	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.000569	0.00161	CcSEcCtD
Carfilzomib—Cough—Gemcitabine—pancreatic cancer	0.000567	0.0016	CcSEcCtD
Carfilzomib—Pain—Sunitinib—pancreatic cancer	0.000565	0.00159	CcSEcCtD
Carfilzomib—Constipation—Sunitinib—pancreatic cancer	0.000565	0.00159	CcSEcCtD
Carfilzomib—Hypertension—Gemcitabine—pancreatic cancer	0.000561	0.00158	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—pancreatic cancer	0.000559	0.00158	CcSEcCtD
Carfilzomib—Asthenia—Tamoxifen—pancreatic cancer	0.000554	0.00156	CcSEcCtD
Carfilzomib—Arthralgia—Gemcitabine—pancreatic cancer	0.000553	0.00156	CcSEcCtD
Carfilzomib—Asthenia—Erlotinib—pancreatic cancer	0.000548	0.00154	CcSEcCtD
Carfilzomib—Infection—Irinotecan—pancreatic cancer	0.000541	0.00152	CcSEcCtD
Carfilzomib—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000533	0.0015	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—pancreatic cancer	0.000532	0.0015	CcSEcCtD
Carfilzomib—Diarrhoea—Tamoxifen—pancreatic cancer	0.000528	0.00149	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—pancreatic cancer	0.000527	0.00149	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.000527	0.00149	CcSEcCtD
Carfilzomib—Infection—Gemcitabine—pancreatic cancer	0.000527	0.00149	CcSEcCtD
Carfilzomib—Body temperature increased—Sunitinib—pancreatic cancer	0.000522	0.00147	CcSEcCtD
Carfilzomib—Diarrhoea—Erlotinib—pancreatic cancer	0.000522	0.00147	CcSEcCtD
Carfilzomib—Oedema peripheral—Docetaxel—pancreatic cancer	0.000522	0.00147	CcSEcCtD
Carfilzomib—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000519	0.00146	CcSEcCtD
Carfilzomib—Anorexia—Irinotecan—pancreatic cancer	0.000519	0.00146	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—pancreatic cancer	0.000518	0.00146	CcSEcCtD
Carfilzomib—Infection—Fluorouracil—pancreatic cancer	0.000518	0.00146	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—pancreatic cancer	0.000517	0.00146	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—pancreatic cancer	0.000516	0.00146	CcSEcCtD
Carfilzomib—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.00051	0.00144	CcSEcCtD
Carfilzomib—Dizziness—Tamoxifen—pancreatic cancer	0.00051	0.00144	CcSEcCtD
Carfilzomib—Anorexia—Gemcitabine—pancreatic cancer	0.000505	0.00143	CcSEcCtD
Carfilzomib—Dizziness—Erlotinib—pancreatic cancer	0.000505	0.00142	CcSEcCtD
Carfilzomib—Anorexia—Fluorouracil—pancreatic cancer	0.000497	0.0014	CcSEcCtD
Carfilzomib—Insomnia—Irinotecan—pancreatic cancer	0.000492	0.00139	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—pancreatic cancer	0.000492	0.00139	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—pancreatic cancer	0.000491	0.00138	CcSEcCtD
Carfilzomib—Vomiting—Tamoxifen—pancreatic cancer	0.000491	0.00138	CcSEcCtD
Carfilzomib—Vomiting—Erlotinib—pancreatic cancer	0.000485	0.00137	CcSEcCtD
Carfilzomib—Dyspnoea—Irinotecan—pancreatic cancer	0.000485	0.00137	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000484	0.00136	CcSEcCtD
Carfilzomib—Headache—Tamoxifen—pancreatic cancer	0.000483	0.00136	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000483	0.00136	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—pancreatic cancer	0.00048	0.00135	CcSEcCtD
Carfilzomib—Insomnia—Gemcitabine—pancreatic cancer	0.00048	0.00135	CcSEcCtD
Carfilzomib—Headache—Erlotinib—pancreatic cancer	0.000478	0.00135	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—pancreatic cancer	0.000478	0.00135	CcSEcCtD
Carfilzomib—Chills—Docetaxel—pancreatic cancer	0.000475	0.00134	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000475	0.00134	CcSEcCtD
Carfilzomib—Asthenia—Sunitinib—pancreatic cancer	0.000474	0.00134	CcSEcCtD
Carfilzomib—Decreased appetite—Irinotecan—pancreatic cancer	0.000473	0.00133	CcSEcCtD
Carfilzomib—Dyspnoea—Gemcitabine—pancreatic cancer	0.000473	0.00133	CcSEcCtD
Carfilzomib—Insomnia—Fluorouracil—pancreatic cancer	0.000471	0.00133	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—pancreatic cancer	0.00047	0.00133	CcSEcCtD
Carfilzomib—Fatigue—Irinotecan—pancreatic cancer	0.000469	0.00132	CcSEcCtD
Carfilzomib—Constipation—Irinotecan—pancreatic cancer	0.000465	0.00131	CcSEcCtD
Carfilzomib—Pain—Irinotecan—pancreatic cancer	0.000465	0.00131	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000465	0.00131	CcSEcCtD
Carfilzomib—Dyspnoea—Fluorouracil—pancreatic cancer	0.000465	0.00131	CcSEcCtD
Carfilzomib—Decreased appetite—Gemcitabine—pancreatic cancer	0.000461	0.0013	CcSEcCtD
Carfilzomib—Nausea—Tamoxifen—pancreatic cancer	0.000458	0.00129	CcSEcCtD
Carfilzomib—Fatigue—Gemcitabine—pancreatic cancer	0.000457	0.00129	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000454	0.00128	CcSEcCtD
Carfilzomib—Pain—Gemcitabine—pancreatic cancer	0.000453	0.00128	CcSEcCtD
Carfilzomib—Constipation—Gemcitabine—pancreatic cancer	0.000453	0.00128	CcSEcCtD
Carfilzomib—Nausea—Erlotinib—pancreatic cancer	0.000453	0.00128	CcSEcCtD
Carfilzomib—Decreased appetite—Fluorouracil—pancreatic cancer	0.000453	0.00128	CcSEcCtD
Carfilzomib—Diarrhoea—Sunitinib—pancreatic cancer	0.000452	0.00127	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000448	0.00126	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—pancreatic cancer	0.000446	0.00126	CcSEcCtD
Carfilzomib—Pain—Fluorouracil—pancreatic cancer	0.000446	0.00126	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—pancreatic cancer	0.000443	0.00125	CcSEcCtD
Carfilzomib—Dizziness—Sunitinib—pancreatic cancer	0.000437	0.00123	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000435	0.00123	CcSEcCtD
Carfilzomib—Body temperature increased—Irinotecan—pancreatic cancer	0.00043	0.00121	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00043	0.00121	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—pancreatic cancer	0.000426	0.0012	CcSEcCtD
Carfilzomib—Vomiting—Sunitinib—pancreatic cancer	0.00042	0.00118	CcSEcCtD
Carfilzomib—Body temperature increased—Gemcitabine—pancreatic cancer	0.000419	0.00118	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—pancreatic cancer	0.000417	0.00118	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000415	0.00117	CcSEcCtD
Carfilzomib—Headache—Sunitinib—pancreatic cancer	0.000414	0.00117	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—pancreatic cancer	0.000413	0.00116	CcSEcCtD
Carfilzomib—Body temperature increased—Fluorouracil—pancreatic cancer	0.000412	0.00116	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000403	0.00114	CcSEcCtD
Carfilzomib—Cough—Docetaxel—pancreatic cancer	0.000402	0.00113	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—pancreatic cancer	0.0004	0.00113	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—pancreatic cancer	0.000398	0.00112	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—pancreatic cancer	0.000392	0.00111	CcSEcCtD
Carfilzomib—Nausea—Sunitinib—pancreatic cancer	0.000392	0.00111	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—pancreatic cancer	0.000391	0.0011	CcSEcCtD
Carfilzomib—Asthenia—Irinotecan—pancreatic cancer	0.000391	0.0011	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.00039	0.0011	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—pancreatic cancer	0.000386	0.00109	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000384	0.00108	CcSEcCtD
Carfilzomib—Asthenia—Gemcitabine—pancreatic cancer	0.00038	0.00107	CcSEcCtD
Carfilzomib—Infection—Docetaxel—pancreatic cancer	0.000374	0.00105	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000372	0.00105	CcSEcCtD
Carfilzomib—Diarrhoea—Irinotecan—pancreatic cancer	0.000372	0.00105	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—pancreatic cancer	0.00037	0.00104	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000368	0.00104	CcSEcCtD
Carfilzomib—Diarrhoea—Gemcitabine—pancreatic cancer	0.000363	0.00102	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—pancreatic cancer	0.000362	0.00102	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000361	0.00102	CcSEcCtD
Carfilzomib—Dizziness—Irinotecan—pancreatic cancer	0.00036	0.00102	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—pancreatic cancer	0.000359	0.00101	CcSEcCtD
Carfilzomib—Diarrhoea—Fluorouracil—pancreatic cancer	0.000357	0.00101	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000355	0.001	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—pancreatic cancer	0.000352	0.000992	CcSEcCtD
Carfilzomib—Vomiting—Irinotecan—pancreatic cancer	0.000346	0.000976	CcSEcCtD
Carfilzomib—Dizziness—Fluorouracil—pancreatic cancer	0.000345	0.000972	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000343	0.000967	CcSEcCtD
Carfilzomib—Headache—Irinotecan—pancreatic cancer	0.000341	0.000962	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—pancreatic cancer	0.00034	0.00096	CcSEcCtD
Carfilzomib—Vomiting—Gemcitabine—pancreatic cancer	0.000337	0.000951	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—pancreatic cancer	0.000335	0.000946	CcSEcCtD
Carfilzomib—Headache—Gemcitabine—pancreatic cancer	0.000332	0.000937	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—pancreatic cancer	0.000332	0.000935	CcSEcCtD
Carfilzomib—Vomiting—Fluorouracil—pancreatic cancer	0.000331	0.000935	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000329	0.000927	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—pancreatic cancer	0.000327	0.000922	CcSEcCtD
Carfilzomib—Headache—Fluorouracil—pancreatic cancer	0.000327	0.000921	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000326	0.000918	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—pancreatic cancer	0.000324	0.000915	CcSEcCtD
Carfilzomib—Nausea—Irinotecan—pancreatic cancer	0.000323	0.000912	CcSEcCtD
Carfilzomib—Pain—Docetaxel—pancreatic cancer	0.000322	0.000907	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—pancreatic cancer	0.000322	0.000907	CcSEcCtD
Carfilzomib—Chills—Epirubicin—pancreatic cancer	0.000321	0.000904	CcSEcCtD
Carfilzomib—Nausea—Gemcitabine—pancreatic cancer	0.000315	0.000888	CcSEcCtD
Carfilzomib—Nausea—Fluorouracil—pancreatic cancer	0.00031	0.000873	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000307	0.000865	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—pancreatic cancer	0.000301	0.000848	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—pancreatic cancer	0.000299	0.000843	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—pancreatic cancer	0.000297	0.000839	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—pancreatic cancer	0.000297	0.000836	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—pancreatic cancer	0.000287	0.00081	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—pancreatic cancer	0.000278	0.000785	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—pancreatic cancer	0.000278	0.000785	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—pancreatic cancer	0.000277	0.00078	CcSEcCtD
Carfilzomib—Cough—Epirubicin—pancreatic cancer	0.000271	0.000765	CcSEcCtD
Carfilzomib—Asthenia—Docetaxel—pancreatic cancer	0.00027	0.000761	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—pancreatic cancer	0.000268	0.000757	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—pancreatic cancer	0.000266	0.00075	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—pancreatic cancer	0.000265	0.000747	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—pancreatic cancer	0.000258	0.000726	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—pancreatic cancer	0.000257	0.000726	CcSEcCtD
Carfilzomib—Infection—Epirubicin—pancreatic cancer	0.000252	0.000711	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—pancreatic cancer	0.000251	0.000708	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—pancreatic cancer	0.000249	0.000702	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000248	0.000701	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—pancreatic cancer	0.000248	0.000701	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—pancreatic cancer	0.000245	0.000691	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—pancreatic cancer	0.000242	0.000682	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—pancreatic cancer	0.000239	0.000675	CcSEcCtD
Carfilzomib—Headache—Docetaxel—pancreatic cancer	0.000236	0.000665	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—pancreatic cancer	0.000233	0.000658	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000231	0.000652	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00023	0.000648	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—pancreatic cancer	0.00023	0.000647	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—pancreatic cancer	0.000226	0.000638	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—pancreatic cancer	0.000224	0.000631	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—pancreatic cancer	0.000223	0.00063	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—pancreatic cancer	0.000221	0.000622	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—pancreatic cancer	0.000219	0.000617	CcSEcCtD
Carfilzomib—Pain—Epirubicin—pancreatic cancer	0.000217	0.000612	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—pancreatic cancer	0.000217	0.000612	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000214	0.000603	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—pancreatic cancer	0.000212	0.000599	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—pancreatic cancer	0.000209	0.00059	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—pancreatic cancer	0.000204	0.000576	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—pancreatic cancer	0.000202	0.000571	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—pancreatic cancer	0.000201	0.000566	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—pancreatic cancer	0.000201	0.000566	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—pancreatic cancer	0.000201	0.000566	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—pancreatic cancer	0.000186	0.000523	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—pancreatic cancer	0.000182	0.000513	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—pancreatic cancer	0.000174	0.00049	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—pancreatic cancer	0.000168	0.000475	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—pancreatic cancer	0.000168	0.000473	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—pancreatic cancer	0.000161	0.000455	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—pancreatic cancer	0.000161	0.000453	CcSEcCtD
Carfilzomib—Headache—Epirubicin—pancreatic cancer	0.000159	0.000448	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—pancreatic cancer	0.000155	0.000438	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—pancreatic cancer	0.000151	0.000425	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—pancreatic cancer	0.000149	0.000421	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—pancreatic cancer	0.000147	0.000415	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—pancreatic cancer	0.000139	0.000393	CcSEcCtD
Carfilzomib—PSMB5—Disease—PTEN—pancreatic cancer	2.76e-05	7.72e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTEN—pancreatic cancer	2.76e-05	7.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTEN—pancreatic cancer	2.76e-05	7.72e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—SRC—pancreatic cancer	2.73e-05	7.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTEN—pancreatic cancer	2.72e-05	7.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CASP3—pancreatic cancer	2.71e-05	7.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CASP3—pancreatic cancer	2.7e-05	7.55e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CB—pancreatic cancer	2.67e-05	7.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CB—pancreatic cancer	2.67e-05	7.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CB—pancreatic cancer	2.67e-05	7.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—pancreatic cancer	2.67e-05	7.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—pancreatic cancer	2.67e-05	7.47e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—pancreatic cancer	2.67e-05	7.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—pancreatic cancer	2.66e-05	7.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—pancreatic cancer	2.66e-05	7.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—pancreatic cancer	2.66e-05	7.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—pancreatic cancer	2.65e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—pancreatic cancer	2.65e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—pancreatic cancer	2.65e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—pancreatic cancer	2.64e-05	7.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CB—pancreatic cancer	2.63e-05	7.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—pancreatic cancer	2.63e-05	7.37e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—pancreatic cancer	2.63e-05	7.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—pancreatic cancer	2.63e-05	7.35e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CTNNB1—pancreatic cancer	2.61e-05	7.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—pancreatic cancer	2.61e-05	7.3e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CTNNB1—pancreatic cancer	2.6e-05	7.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	2.58e-05	7.21e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—pancreatic cancer	2.57e-05	7.2e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—pancreatic cancer	2.57e-05	7.18e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CD—pancreatic cancer	2.56e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CD—pancreatic cancer	2.56e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CD—pancreatic cancer	2.56e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—pancreatic cancer	2.56e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—pancreatic cancer	2.56e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SRC—pancreatic cancer	2.56e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SRC—pancreatic cancer	2.56e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SRC—pancreatic cancer	2.56e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—pancreatic cancer	2.55e-05	7.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—pancreatic cancer	2.55e-05	7.14e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PTEN—pancreatic cancer	2.55e-05	7.13e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PTEN—pancreatic cancer	2.53e-05	7.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CD—pancreatic cancer	2.53e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SRC—pancreatic cancer	2.52e-05	7.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GLP1R—pancreatic cancer	2.49e-05	6.98e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	2.49e-05	6.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—pancreatic cancer	2.47e-05	6.91e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—pancreatic cancer	2.47e-05	6.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—pancreatic cancer	2.47e-05	6.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—pancreatic cancer	2.47e-05	6.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—pancreatic cancer	2.47e-05	6.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—pancreatic cancer	2.47e-05	6.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—pancreatic cancer	2.46e-05	6.88e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—pancreatic cancer	2.46e-05	6.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—pancreatic cancer	2.46e-05	6.88e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DPYD—pancreatic cancer	2.45e-05	6.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—pancreatic cancer	2.43e-05	6.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—pancreatic cancer	2.43e-05	6.8e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—pancreatic cancer	2.43e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—pancreatic cancer	2.43e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—pancreatic cancer	2.43e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—pancreatic cancer	2.42e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—pancreatic cancer	2.39e-05	6.7e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—pancreatic cancer	2.37e-05	6.64e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—pancreatic cancer	2.36e-05	6.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—pancreatic cancer	2.36e-05	6.61e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—pancreatic cancer	2.35e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A2—pancreatic cancer	2.33e-05	6.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—pancreatic cancer	2.31e-05	6.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—pancreatic cancer	2.31e-05	6.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—pancreatic cancer	2.31e-05	6.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—pancreatic cancer	2.3e-05	6.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—pancreatic cancer	2.29e-05	6.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—pancreatic cancer	2.29e-05	6.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—pancreatic cancer	2.29e-05	6.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—pancreatic cancer	2.29e-05	6.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—pancreatic cancer	2.29e-05	6.41e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—pancreatic cancer	2.29e-05	6.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—pancreatic cancer	2.29e-05	6.41e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—pancreatic cancer	2.29e-05	6.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—pancreatic cancer	2.29e-05	6.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—pancreatic cancer	2.29e-05	6.4e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—pancreatic cancer	2.28e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—pancreatic cancer	2.28e-05	6.37e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—pancreatic cancer	2.27e-05	6.36e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—pancreatic cancer	2.27e-05	6.35e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—pancreatic cancer	2.27e-05	6.35e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—pancreatic cancer	2.26e-05	6.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—pancreatic cancer	2.26e-05	6.33e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—pancreatic cancer	2.26e-05	6.32e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—pancreatic cancer	2.26e-05	6.32e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—pancreatic cancer	2.26e-05	6.32e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—pancreatic cancer	2.25e-05	6.31e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—pancreatic cancer	2.25e-05	6.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—pancreatic cancer	2.24e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—pancreatic cancer	2.24e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—pancreatic cancer	2.24e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—pancreatic cancer	2.23e-05	6.25e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—pancreatic cancer	2.23e-05	6.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—pancreatic cancer	2.23e-05	6.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—pancreatic cancer	2.21e-05	6.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—pancreatic cancer	2.2e-05	6.16e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—pancreatic cancer	2.15e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—pancreatic cancer	2.15e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—pancreatic cancer	2.15e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—pancreatic cancer	2.15e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—pancreatic cancer	2.14e-05	5.99e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—pancreatic cancer	2.12e-05	5.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—pancreatic cancer	2.12e-05	5.92e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—pancreatic cancer	2.12e-05	5.92e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—pancreatic cancer	2.12e-05	5.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—pancreatic cancer	2.12e-05	5.92e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—pancreatic cancer	2.11e-05	5.91e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—pancreatic cancer	2.11e-05	5.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—pancreatic cancer	2.11e-05	5.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—pancreatic cancer	2.11e-05	5.9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—pancreatic cancer	2.11e-05	5.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.1e-05	5.89e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—pancreatic cancer	2.1e-05	5.88e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—pancreatic cancer	2.1e-05	5.87e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—pancreatic cancer	2.09e-05	5.84e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—pancreatic cancer	2.09e-05	5.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—pancreatic cancer	2.08e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—pancreatic cancer	2.07e-05	5.79e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—pancreatic cancer	2.06e-05	5.77e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—pancreatic cancer	2.05e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—pancreatic cancer	2.05e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—pancreatic cancer	2.05e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—pancreatic cancer	2.03e-05	5.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—pancreatic cancer	2e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—pancreatic cancer	2e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—pancreatic cancer	2e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—pancreatic cancer	1.98e-05	5.54e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—pancreatic cancer	1.98e-05	5.54e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—pancreatic cancer	1.98e-05	5.54e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—pancreatic cancer	1.97e-05	5.52e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—pancreatic cancer	1.96e-05	5.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—pancreatic cancer	1.95e-05	5.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—pancreatic cancer	1.95e-05	5.45e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—pancreatic cancer	1.95e-05	5.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—pancreatic cancer	1.95e-05	5.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—pancreatic cancer	1.95e-05	5.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—pancreatic cancer	1.94e-05	5.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—pancreatic cancer	1.94e-05	5.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—pancreatic cancer	1.94e-05	5.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—pancreatic cancer	1.94e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—pancreatic cancer	1.94e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—pancreatic cancer	1.94e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—pancreatic cancer	1.93e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—pancreatic cancer	1.93e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—pancreatic cancer	1.93e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—pancreatic cancer	1.92e-05	5.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—pancreatic cancer	1.92e-05	5.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—pancreatic cancer	1.91e-05	5.36e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—pancreatic cancer	1.9e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD44—pancreatic cancer	1.8e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—pancreatic cancer	1.8e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—pancreatic cancer	1.8e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—pancreatic cancer	1.8e-05	5.04e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—pancreatic cancer	1.8e-05	5.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—pancreatic cancer	1.79e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—pancreatic cancer	1.79e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—pancreatic cancer	1.79e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—pancreatic cancer	1.79e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—pancreatic cancer	1.77e-05	4.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—pancreatic cancer	1.76e-05	4.94e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—pancreatic cancer	1.76e-05	4.91e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—pancreatic cancer	1.75e-05	4.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—pancreatic cancer	1.74e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—pancreatic cancer	1.74e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—pancreatic cancer	1.74e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—pancreatic cancer	1.74e-05	4.87e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—pancreatic cancer	1.73e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCG—pancreatic cancer	1.73e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—pancreatic cancer	1.73e-05	4.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—pancreatic cancer	1.73e-05	4.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—pancreatic cancer	1.73e-05	4.83e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—pancreatic cancer	1.72e-05	4.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—pancreatic cancer	1.72e-05	4.82e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—pancreatic cancer	1.72e-05	4.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—pancreatic cancer	1.72e-05	4.82e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—pancreatic cancer	1.72e-05	4.82e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—pancreatic cancer	1.72e-05	4.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—pancreatic cancer	1.72e-05	4.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—pancreatic cancer	1.71e-05	4.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—pancreatic cancer	1.71e-05	4.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—pancreatic cancer	1.71e-05	4.79e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—pancreatic cancer	1.7e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—pancreatic cancer	1.7e-05	4.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—pancreatic cancer	1.7e-05	4.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—pancreatic cancer	1.69e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—pancreatic cancer	1.66e-05	4.65e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—pancreatic cancer	1.65e-05	4.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—pancreatic cancer	1.63e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—pancreatic cancer	1.63e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—pancreatic cancer	1.63e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STK11—pancreatic cancer	1.62e-05	4.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—pancreatic cancer	1.61e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—pancreatic cancer	1.6e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—pancreatic cancer	1.6e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—pancreatic cancer	1.6e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—pancreatic cancer	1.6e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—pancreatic cancer	1.6e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—pancreatic cancer	1.6e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—pancreatic cancer	1.59e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—pancreatic cancer	1.59e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—pancreatic cancer	1.59e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—pancreatic cancer	1.58e-05	4.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—pancreatic cancer	1.58e-05	4.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—pancreatic cancer	1.57e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—pancreatic cancer	1.57e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—pancreatic cancer	1.57e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—pancreatic cancer	1.57e-05	4.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—pancreatic cancer	1.55e-05	4.33e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—pancreatic cancer	1.48e-05	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—pancreatic cancer	1.48e-05	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—pancreatic cancer	1.48e-05	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—pancreatic cancer	1.47e-05	4.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—pancreatic cancer	1.46e-05	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—pancreatic cancer	1.46e-05	4.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—pancreatic cancer	1.4e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—pancreatic cancer	1.36e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—pancreatic cancer	1.36e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—pancreatic cancer	1.36e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—pancreatic cancer	1.34e-05	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—pancreatic cancer	1.33e-05	3.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—pancreatic cancer	1.33e-05	3.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—pancreatic cancer	1.33e-05	3.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—pancreatic cancer	1.32e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—pancreatic cancer	1.32e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—pancreatic cancer	1.32e-05	3.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—pancreatic cancer	1.31e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—pancreatic cancer	1.3e-05	3.64e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—pancreatic cancer	1.26e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—pancreatic cancer	1.26e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—pancreatic cancer	1.26e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—pancreatic cancer	1.24e-05	3.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOE—pancreatic cancer	1.14e-05	3.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—pancreatic cancer	1.11e-05	3.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—pancreatic cancer	1.11e-05	3.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—pancreatic cancer	1.11e-05	3.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—pancreatic cancer	1.1e-05	3.07e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.03e-05	2.87e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—pancreatic cancer	9.9e-06	2.77e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	9.02e-06	2.52e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	7.86e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—pancreatic cancer	7.79e-06	2.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—pancreatic cancer	6.79e-06	1.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	4.79e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—pancreatic cancer	3.91e-06	1.1e-05	CbGpPWpGaD
